With regard to potential therapeutic applications, it is worth noting that the region of the TERT promoter that frequently carries TERT promoter mutations in BC, which are absent in normal bladder cells, can presumably become the target of anti-cancer therapy, including novel TERT-based immunotherapies, which could be tailored to patients whose tumors harbor these mutations [88,89]. This evidence concerns the gene TERT and cancer.